​​​​​

IBD Center Conference

3rd Annual IBD Center Conference

April 14, 2018

Baylor Charles A. Sammons Cancer Center • Dallas, Texas

Program Objectives

Tremendous progress has occurred in our understanding of IBD mechanisms. In the future, the selection of treatment will be personalized, i.e. will be based on the genetic composition, microbiomic profile and immunologic phenotype of the patient. This CME course will review the current state of the art and outlook for mechanism-based therapies. The course will also address other aspects of individualized management , including smoking cessation, transition from pediatric to adult IBD care, psychiatric treatment and management of dermatologic disease.

  • Stratify patients according to short and long term risk
  • Select therapy according to patient risk
  • Identify patients who are good candidates for immunomodulatory therapy
  • Select biologic agent tailored to the needs of the individual patient
  • Identify the different approaches to smoking cessation

Statement of Need

The two main Inflammatory Bowel Diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, progressive idiopathic inflammatory disorders of the gastrointestinal (GI) tract. CD can affect any part of the GI tract, whereas UC affects the colon only.

A study using data from 2003-2004 estimated that approximately 436,000 Americans have CD and 512,000 have UC 1. The prevalence of CD was estimated at 151 per 100,000, while UC prevalence was estimated 178 per 100,000 1. A subsequent study using 2009 data estimated that 1,171,000 Americans have IBD (565,000 CD and 593,000 UC) 2. The protracted nature of these diseases exerts a major toll on patients in terms of need for chronic medical therapies, hospitalizations, surgery, health-related quality of life, economic productivity and social functioning. CD is responsible for $3.48 billion in total costs in the United States 3

Management of IBD is a complex, multidisciplinary process, made all the more difficult by the clinical heterogeneity of IBD and the lack of comparative effectiveness studies. Numerous studies have demonstrated practice variation, for example in the use of anti-inflammatory therapies, vaccinations and surgery. A recent study found significant variation among seven major US referral centers in the treatment of CD with immunomodulators 4. The practice variation points to areas of potential improvement in the quality of IBD care.

References
  1. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9.
  2. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population. Dig Dis Sci. 2013; 58(2): 519–525.
  3. Ganz ML, Sugarman R, Wang R, Hansen BB, Håkan-Bloch J. The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey. Inflamm Bowel Dis. 2016 May;22(5):1032-41.
  4. Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1197-200.

Program Agenda

Presentation materials, when available, maybe downloaded in pdf format. The password will be emailed to participants prior to the activity.

Saturday, April 14, 2018

  • 7 a.m.

    Registration, continental breakfast and exhibits

  • 7:45 a.m.

    Welcome and course overview

  • Session One

    8 a.m.

    Progress Towards an Integrated Classification of IBD

    Peter J. Mannon, MD

  • 8:30 a.m.

    The Intestinal Microbiome in IBD: Therapeutic Implications

    R. Balfour Sartor, MD

  • 8:50 a.m.

    Risk Stratification in IBD

    Themistocles Dassopoulos, MD

  • 9:10 a.m.

    Individualizing Therapy According to Disease Mechanism

    Peter J. Mannon, MD

  • 9:30 a.m.

    Panel Discussion/Q&A

  • 9:50 a.m.

    Break and Exhibits

  • Session Two

    10 a.m.

    Do Immunomodulators Still Have a Place in IBD?

    Christopher Johnson, MD, PhD

  • 10:20 a.m.

    Selecting the "Right" First-Line Biologic Agent

    William Tremaine, MD

  • 10:40 a.m.

    New Therapies on the Horizon

    Themistocles Dassopoulos, MD

  • 11 a.m.

    Should Deep Remission Be a Treatment Goal? Yes

    R. Balfour Sartor, MD

  • 11:20 a.m.

    Should Deep Remission Be a Treatment Goal? No

    William Tremaine, MD

  • 11:40 a.m.

    Panel Discussion/Q&A

  • 12 p.m.

    Lunch and case study discussions/exhibits

  • Session Three

    1 p.m.

    Examples of Complex IBD Surgery

    Walter R. Peters, Jr., MD, MBA

  • 1:20 p.m.

    Recognizing and Treating Psychiatric Disease

    Ann Marie Warren, PhD, ABPP

  • 1:40 p.m.

    Transitioning from Pediatric to Adult IBD Care

    Ashish S. Patel, MD

  • 2 p.m.

    Helping Your Patient Quit Smoking

    Christopher Johnson, MD, PhD

  • 2:20 p.m.

    Dermatologic Disease in IBD: What the Gastroenterologist Needs to Know

    Alan Menter, MD

  • 2:40 p.m.

    Panel Discussion/Q&A

  • 3 p.m.

    Adjournment

Accreditation and Credit Designation

Accreditation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Location

Meeting

The conference is held at the Baylor Charles A. Sammons Cancer Center on the Baylor University Medical Center at Dallas campus.

The Baylor University Medical Center campus encompasses many hospital buildings, programs and office buildings. Avariety of parking options are available, including self-park, valet, covered parking and private lots.

Download campus map

Address
Baylor Charles A. Sammons Cancer Center
Tom Hunt Auditorium, 10th Floor
3410 Worth Street
Dallas, TX 75246

Registration

Physicians

$75

APPs

$75

Fellows

$0

Contact Us

Check out all of our upcoming learning opportunities